title: Eosinophilic myeloproliferative disorders.
abstract: Despite recent attempts to define and classify patients with marked eosinophilia and features consistent with myeloproliferative disease, areas of controversy remain. These are particularly apparent in situations in which multiple lineages are involved in a clonal process and clinical manifestations are overlapping. Although the introduction of new molecular diagnostics and targeted therapies has begun to clarify the boundaries between some of these disorders, several questions remain with respect to the classification of patients with myeloproliferative hypereosinophilic syndrome (HES) of unknown etiology.
authors.affiliation: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. aklion@niaid.nih.gov
authors.forename: Amy D
authors.initials: AD
authors.lastname: Klion
mesh_terms: D004802:Eosinophilia / Q000145:classification / Q000150:complications* / Q000473:pathology / Q000628:therapy; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications / Q000473:pathology; D007938:Leukemia / Q000150:complications; D034721:Mastocytosis, Systemic / Q000150:complications; D009196:Myeloproliferative Disorders / Q000145:classification / Q000150:complications* / Q000473:pathology / Q000628:therapy; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000378:metabolism
chemical_list: D020796:Receptor, Platelet-Derived Growth Factor alpha